Kestra Medical Technologies, Ltd. (KMTS) Stock

About Kestra Medical Technologies, Ltd.

Kestra Medical Technologies, Ltd. is led by CEO Brian Webster, employs 300 people, headquartered in US, publicly traded since 2025.

Kestra Medical Technologies, Ltd. (KMTS) stock trades at $28.76 with a market capitalization of $1.71B. The stock is valued at a negative price-to-earnings (P/E) ratio of -10.27, reflecting a net loss over the last twelve months, price-to-book of 7.22, price-to-sales of 15.06. Over the past 52 weeks the stock has ranged between $17.34 and $30.00, and currently trades 4.1% below its 52-week high.

On profitability, Kestra Medical Technologies, Ltd. generates a return on equity (ROE) of -64.18% (negative, reflecting a net loss), return on capital employed of -47.99%, an operating margin of -176.67%, a net profit margin of -140.43%.

Kestra Medical Technologies, Ltd. by the numbers, 2020–2026

Compounded, revenue has grown —% a year over five years, 128.2% over three, 58.3% over the last twelve months. Net profit was $-132.0M in 2026.

The most recent net margin is -140.43%. On a trailing twelve-month basis to Jun '26, revenue is $108.0M and net profit $-150.0M.

Borrowings stand at $47.0M, cash from operations was $-82.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged 2.5% over five years, and was -50.8% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Kestra Medical Technologies, Ltd. (KMTS) — frequently asked questions